ARDS Aridis Pharmaceuticals Inc.

7.61
+0.2  (+3%)
Previous Close 7.41
Open 7.55
Price To Book 7.77
Market Cap 67,852,349
Shares 8,912,227
Volume 8,027
Short Ratio
Av. Daily Volume 20,497
Stock charts supplied by TradingView

NewsSee all news

  1. Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer

    SAN JOSE, Calif., Jan. 2, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal

  2. Aridis Pharmaceuticals Announces Third Quarter 2019 Results

    SAN JOSE, Calif., Nov. 13, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal

  3. Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer

    SAN JOSE, Calif., Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

  4. Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

    SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  5. Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim data due 1Q 2020 with final data due early 2021.
AR-301 (Salvecin)
Staphylococcus aureus
Phase 2 trial did not met primary endpoint - September 3, 2019.
AR-105 (Aerucin)
Pseudomonas aeruginosa
Phase 2/3 trial pending AR-105 data.
AR-101 (Aerumab)
Pseudomonas aeruginosa
Phase 1/2 data in healthy subjects due 1Q 2020 and from cystic fibrosis patients in 2Q 2021.
AR-501
Chronic bacterial lung infections in patients with cystic fibrosis (CF)

Latest News

  1. Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer

    SAN JOSE, Calif., Jan. 2, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal

  2. Aridis Pharmaceuticals Announces Third Quarter 2019 Results

    SAN JOSE, Calif., Nov. 13, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal

  3. Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer

    SAN JOSE, Calif., Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

  4. Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology

    SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  5. Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  6. Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    SAN JOSE, Calif., Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat

  7. Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    SAN JOSE, Calif., Sept. 8, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening

  8. Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa

    SAN JOSE, Calif., Sept. 3, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening